NEUROENDOCRINE TUMORS

This phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high-dose standard drug (Octreotide LAR) in 196 adults with advanced neuroendocrine tumors that could not be removed by surgery. The goal was to see which treatment better delayed tumor growt…

This study tests a new radiation treatment (PRRT with 177Lu-Edotreotide) against a standard targeted drug (everolimus) in 324 people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. The goal is to see which treatment better delays tumor…

This early-phase study tests a new combination treatment for people with advanced neuroendocrine tumors that have stopped responding to standard therapies. The trial combines a targeted drug (cabozantinib) with a type of radiation therapy (PRRT) to see if they work better togethe…

This study tests a combination of two immunotherapy drugs, ipilimumab and nivolumab, in people with rare cancers that are known to respond to immunotherapy. The cancers include certain neuroendocrine tumors, biliary tract cancers, gynecological cancers, and mismatch repair defici…

This early-phase study tests if giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two injections into the liver artery, and researchers will comp…

This study tests a radioactive drug called Lu-DOTATATE in people with neuroendocrine tumors that have a specific marker (somatostatin receptors). The treatment delivers radiation directly to tumor cells, and the dose is adjusted for each patient. The goal is to see if it can stop…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system fight cancer) and temozolomide (a chemotherapy drug)—in people with small-cell lung cancer that has returned or stopped responding to treatment, or advanced neuroendocrine tumors.…

This study tests an experimental drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth, and their progress is…

This study tests a new treatment for people with advanced high-grade neuroendocrine tumors (a rare and fast-growing cancer). It combines chemotherapy with two immunotherapy drugs, first to shrink tumors and then to keep them under control. The goal is to see if this approach impr…

This study tests whether combining two drugs (atezolizumab and tivozanib) can help the immune system attack cancers that usually don't respond to immunotherapy, like certain prostate, pancreatic, and breast cancers. About 29 adults with advanced or metastatic disease who have alr…

This study tests a targeted radiation therapy (PRRT with 177Lu-Edotreotide) against the best standard treatments for people with aggressive neuroendocrine tumors in the gut or pancreas. About 259 adults whose tumors have specific markers will be randomly assigned to receive eithe…

This study tests a new drug called 212Pb-DOTAMTATE that delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have a specific marker (somatostatin receptor) and have worsened after standard treatments. The goal is to see if the drug can shr…

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This early-stage study tests a new radioactive drug called [212Pb] VMT-alpha-NET in 24 adults with advanced neuroendocrine tumors that have stopped responding to other treatments. The main goal is to find a safe dose for future studies, not to provide direct benefit. Participants…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma are randomly assigned to receive either avelumab or a placebo. The main goal is to se…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced neuroendocrine prostate cancer that has spread. The goal is to see if the treatment can slow tumor growth. About 45 participants will receive the drugs in 21-day cycles for up to 35…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-DOTATOC to find neuroendocrine tumors (NETs) and other related cancers. The scan targets a molecule found in high amounts on these tumor cells. Researchers want to see if this scan is safer and …

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 adults with metastatic neuroendocrine tumors. The goal is to see which scan best detects all tumor spots and whether different scans show different results. Findings may help doctors …

This study aims to improve how total-body PET scans work for people with prostate cancer, breast cancer, or neuroendocrine tumors. Researchers will collect extra data from FDA-approved imaging agents during routine scans. Only 9 participants are needed, and the goal is to learn m…

This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are monitoring for long-term side effects, including secondary cancers, and tracking overall safety. The goal is to better understand the risks of th…

This study is testing new guidelines for reading PET scans in people with neuroendocrine tumors. The goal is to see if these new criteria can more accurately predict whether a person's cancer improves, worsens, or stays the same after treatment. About 11 participants who are alre…

This study involves 40 adults with a specific type of neuroendocrine tumor (G2-G3 GEP-NET). Researchers are using two different PET scans to see how active the tumors are and whether the extra scan helps doctors choose the best treatment. The goal is to learn more about tumor beh…

This study looks at 500 people with advanced neuroendocrine tumors to find the best order of two treatments: surufatinib and somatostatin analogs. Researchers compare starting with surufatinib then switching to somatostatin analogs versus the opposite order. The goal is to see wh…

This study does not provide new treatment. Instead, it follows up to 1,150 people who previously received experimental cell or gene therapies for cancers like melanoma and neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years to mo…

This study follows over 2,500 people with neuroendocrine tumors (NETs) to learn how symptoms and treatments affect their quality of life. Participants fill out surveys about their well-being and care experiences for up to 18 months. The goal is to find which treatments work best …